Stock market analyst Somil Mehta of Sharekhan has maintained 'buy' rating on Ranbaxy stock with short term target of Rs 485.

According to analyst, the investors can buy the stock stop loss of Rs 434.

Today, the stock opened at Rs 446.50 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 240 on BSE.

Current EPS & P/E ratio stood at 16.19 and 28.11 respectively.

Ranbaxy Labs may close down one of its biggest international bulk drug production facilities located at Mohali, and is sourcing few products produced at the plant from local drug manufacturers previous to the closedown. Even though Ranbaxy's biggest drug manufacturer has been eyeing to outsource manufacturing of some products, it decided to limit the policy to small markets. Ranbaxy Laboratories (Ranbaxy) along with Daiichi Sankyo Co on June 10 declared that Ranbaxy has introduced a generic edition of Prasugrel in the Indian market.

Prasugrel, known as prasita is an antiplatelet agent for preventing atherothrombotic events in sufferers having acute coronary syndrome undergoing percutaneous coronary intervention.